International Journal on Science and Technology (IJSAT)
E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

Compounding Medications: Forgotten Past or Bright Future?

Dr. Nirlepkumar Patel

M.S Rph, Pharmacist, Independent Researcher,
Tennessee USA
Nirlepkumar1987@gmail.com

Abstract

When it comes to providing patients with individualized therapies, compounded drugs have been an indispensable tool throughout the whole history of pharmacy. Before the advent of medicines manufactured in large quantities, the conventional method for synthesizing drugs was known as compounding. Despite this, its peak time has become a thing of the past due to developments in industrial manufacturing and regulatory control. Compounding is a crucial service for patients who want exact doses, formulations devoid of allergens, or medications that have been stopped. However, compounding has recently experienced a drop in popularity due to the standardization of medicines, even though it has been around for a considerable amount of time.

On the other hand, the modern healthcare system is witnessing a revival of this practice. Several factors, including the development of tailored medicine, adjustments to regulatory policies, and creative technological advancements, are driving this revival. Nevertheless, problems associated with quality assurance, compliance with regulations, and safety concerns continue to manifest. The future of compounding will be determined by technology's capacity to incorporate innovation while upholding high safety compliance criteria. It can improve conventional pharmaceutical procedures to assure the availability of patient-specific drugs if it is appropriately acknowledged and controlled. To determine if compounding is a process that is no longer relevant or whether it is an essential component of the future of healthcare, this article investigates both the benefits and the drawbacks of compounding.

Keywords: Compounding Medication, Conventional Medicine, Evolution, Advantages, Accessibility

INTRODUCTION

The production of individualized pharmaceuticals through the combination of science and art is known as pharmaceutical compounding, and it has been an essential part of medical treatment for a very long time. Before the advent of mass production of pharmaceuticals, pharmacists were responsible for the routine preparation of individualized formulations for each patient being treated. During the twentieth century, the pharmaceutical industry became highly industrialized, which led to a drop in the popularity of compounding. This loss was attributed to commercially made medications' advantages, uniformity, convenience, and regulatory monitoring. Despite its weakened status in mainstream medicine, pharmaceutical compounding remains crucial for individuals whose special medical needs are

not covered by generic formulations of frequently used pharmaceuticals. This is because generic formulations of medications are not available. Individuals who fall into this category can need different administration methods, formulations devoid of allergens, or individualized doses. Compounding has seen a resurgence in interest for several reasons, including recent technological developments and an increased focus on individualized medicine. Compounding has been identified as a potential bridge between conventional pharmacy procedures and cutting-edge medical technologies because of this.

Regarding regulatory compliance, quality control, and patient safety, the return of compounding brings several issues. The pharmaceutical industry has come under criticism because of concerns over standardization, control, and the hazards connected with drugs not developed commercially. After considering all these aspects, the function of compounding in modern medicine continues to be a contentious issue. This article looks at the historical evolution of pharmaceutical compounding, including its fall and subsequent revival, and the reasons defining its future trajectory. Through an analysis of its benefits, drawbacks, and the legal framework around it, this study aims to evaluate if compounding is a mere remnant of the past or an essential component of the future healthcare system.

HISTORY OF COMPOUNDING MEDICATIONS

Throughout several millennia, the process of compounding pharmaceuticals has developed in tandem with the fields of pharmacy and healthcare. Before the advent of drugs manufactured in large quantities, the process entailed the production of prescriptions, the compounding of those prescriptions, and the customization of those prescriptions to match the particular needs of individual patients. The relevance of compounding has changed throughout time, yet it continues to be an essential part of contemporary medical practice. The compounding process may be traced back to ancient cultures that developed it. In approximately 1550 BCE, the Ebers Papyrus, considered one of the first medical writings from ancient Egypt, provided documentation of several therapeutic formulas. These formulations included herbal combinations, ointments, and potions. Egyptian medical practitioners painstakingly developed natural remedies such as minerals, oils, and honey to treat various illnesses. The compounding process was developed further during the time of the Greeks and Romans, which lasted from 400 BCE to 200 CE. Hippocrates, a well-known Greek physician who lived from 460 to 370 BCE and is frequently referred to as the "Father of Medicine," significantly contributed to developing the notion of precision medicine by highlighting the need for tailored care. Galen, a Roman physician from 129 to 216 CE, is credited with establishing systematic procedures for manufacturing medicinal drugs. These approaches resulted in formulations with an ideal active-to-inert constituents ratio. He described the fundamentals of compounding, which have been applied for several years, through his Galenic Pharmacy publications. Because of their expertise in compounding, apothecaries, also known as early pharmacists, were in high demand during the Middle Ages, which lasted from the fifth to the fifteenth century. Traditional medicine practitioners employed treatments generated from plants, minerals, and animal products. These treatments were informed by knowledge passed down from generation to generation. The compounding techniques began to be affected by scientific discoveries throughout the Renaissance period, which lasted from the 14th to the 17th century. Two important publications that made this procedure more straightforward were the United States Pharmacopoeia (USP), initially published in 1820, and the London Pharmacopoeia (1618). Both publications were designed to ensure that medication formulations were of a consistent and superior quality. These texts may provide

instructions for measuring, combining, and preparing chemicals for therapeutic use. Pharmacists may find these guidelines within these texts.

The Industrial Revolution, which took place between the 18th and 19th centuries, was a time that was highly significant for the pharmaceutical industry. The development of mechanical manufacturing allowed pharmaceutical corporations to begin the mass production of standardized drugs, reducing the need for conventional compounding operations. Following this modification, there was an increase in homogeneity, an improvement in stability, and an improvement in access to drugs. It wasn't until the beginning of the twentieth century that most pharmacies stopped compounding and started selling already-made pharmaceuticals. The general usage of compounding decreased, even though it continued to be necessary in some situations, such as for children or those who had allergies to over-the-counter medications. Mass-produced pharmaceuticals became the favored alternative because of their established safety profiles and standardized formulas. At the same time, regulatory authorities such as the Food and Drug Administration (FDA) of the United States increased the quality control methods they implemented. An increase in the interest rate that compounded in spite of the widespread availability of medications manufactured in large quantities, compounding has witnessed a boom in popularity over the last several decades. The shortcomings of mass-produced drugs have been brought to light because of the growing need for tailored therapy, which has contributed to the resurgence of interest in customized medicine. Compounding pharmacies are necessary for dealing with patients who have requirements, such as those who require precise doses, different routes of administration (for example, liquids rather than pills), or formulations that are appropriate for individuals who have food allergies. If a patient requires a formulation of a medication that has been discontinued or is no longer accessible from a commercial producer, a compounding Pharmacist can reproduce the formulation for the patient. Technological advancements and breakthroughs in pharmaceutical research have expanded the scope of compounded treatments and increased their safety. Sterile compounding, sophisticated medication delivery systems, and bioidentical hormone treatment are all included in this category.

Organizations such as the United States Pharmacopeia (USP) and state pharmacy boards always work to improve their standards to guarantee the safety, effectiveness, and high quality of compounded pharmaceuticals. As a result of this comeback, questions have been raised over quality control, regulatory monitoring, and safety management. The meningitis epidemic at the New England Compounding Center (NECC) in 2012 was a noteworthy event that brought to light the dangers related to compounding that is not conducted under proper management. Therefore, regulatory organizations have increased the required specifications to improve the level of safety and compliance within the compounding industry. It is a Protocol. The progression of compounding drugs from a fundamental requirement to a specialized profession in modern healthcare illustrates the connection between the past and the future of innovations. Compounding has become more critical throughout history; nonetheless, it remains of utmost importance for patients who require specialized treatment or not commonly available pharmaceuticals. The capacity of compounding as a discipline to adjust to new technical developments, shifting legislative requirements, and patient-centered healthcare objectives will determine the field's trajectory in the years to come.

EVOLUTION OF COMPOUNDING MEDICATIONS

Over the course of its history, medicinal compounding has seen substantial development, transitioning from its roots in traditional herbal treatments to a highly developed specialty within contemporary pharmacy. Scientific research, technological advancements, legal frameworks, and the ever-evolving requirements of patients have all played a role in the development. In the past, compounding was a significant force in the pharmaceutical industry, but as manufacturing bulk medications became more widespread, compounding began to wane. Despite this, it is seeing a resonant rebound due to the growing need for tailored therapy. In the next part, we will investigate the key milestones that have occurred during the development of compounding and its use in modern medicine.

In the first place, a brief historical overview of herbal medicine and primitive pharmacy: Ancient civilizations like Egypt, Mesopotamia, Greece, and Rome were the first to develop the process of synthesizing therapeutic substances. Throughout history, traditional medicine practitioners have utilized a combination of herbs, minerals, and animal derivatives to cure individuals suffering from certain diseases. Extracted from the Ebers Papyrus, an Egyptian medical manuscript from around 1550 BCE, are the first documented instances of compounded therapies. Hippocrates, who lived from 460 to 370 BCE, and Galen, who lived from 129 to 216 CE, were two ancient Greek and Roman physicians who made significant contributions to the field of medicine by highlighting the need for individualized treatment plans. Through his ideas of Galenic Pharmacy, Galen laid the groundwork for the profession of pharmaceutical compounding and profoundly impacted the medical practices of the time for centuries.



Fig. 1: A quick rundown of the main steps involved in compounding at a pharmacy

The Standardization of Pharmaceutical Formulations: The Historical Period of the Apothecary: The practice of compounding developed into a specialized profession throughout the Middle Ages, which saw the rise of apothecaries from around 500 to approximately 1500. Utilizing their expertise in botany and observations of the natural world, these forward-thinking pharmacists were tasked with developing

and providing therapeutic remedies. In a time when every single medicinal product was made by hand, their function was necessary. A period of gradually structured medical procedures began during the Renaissance, which lasted from the 14th to the 17th century. Scientific achievements characterized this period. Standardizing drug formulations and improving quality control in compounded pharmaceuticals were two of the goals pursued in constructing pharmacopeias, such as the United States Pharmacopoeia (USP, 1820) and the London Pharmacopoeia (1618).

The decline of traditional compounding is the third main concern. The consequence of industrialization: Due to the introduction of mechanical drug synthesis during the Industrial Revolution (18th-19th century), there was a decrease in the requirement for significant compounding in pharmacies. Pharmaceutical companies created pre-formulated, standardized drugs to improve the speed, uniformity, and accessibility of the medication supply. Since the pharmaceutical business had completely embraced mass manufacturing by the beginning of the twentieth century, compounding was already a significantly less common practice. Because of the stringent standards that regulatory authorities like the Food and Drug Administration (FDA) of the United States of America enforced to manufacture drugs, pharmacies were increasingly required to sell medications already available for commercial use rather than relying on conventional compounding. Compounding was formerly the dominant method of manufacturing pharmaceuticals; however, it has since developed into a specialized specialty in various medical sectors, including veterinary medicine, hormone replacement treatment, and pediatric medicine. In the latter half of the 20th century and the early 21st century, compounding had a resurgence. The practice of compounding had a comeback in the latter half of the 20th century and the early 21st century due to several variables, including the following:

- Personalized medicine: Recent developments in science and genetics have highlighted the necessity of individualized treatment plans, which has increased the demand for pharmaceutical formulations suited to specific conditions.
- Compounding pharmacies can intervene and re-formulate medications in the event that commercial manufacturers discontinue production or have supply chain challenges. This allows them to provide drug deprivation and cancellation services.
- Compounding pharmacies may provide patients with various dosage forms in addition to the commonly used pill and capsule forms. These may include liquid, transdermal, or sublingual choices.
- The United States Pharmacopeia (USP) and the Pharmacy Compounding Accreditation Board (PCAB) are two organizations that have set new safety criteria to guarantee the efficacy and quality of compounded medications. These organizations have also worked to amend existing regulations.

The resurgence of the industry spurred regulators to increase their level of scrutiny. The risks associated with compounding procedures that are not regulated have been brought to light by noteworthy safety accidents, such as the epidemic of meningitis that occurred at the New England Compounding Center (NECC) in 2012. In response, state pharmacy boards and the Food and Drug Administration have increased their regulation of compounding to guarantee that it is safe and relevant to contemporary medicine. Innovative strategies that include novel concepts are available when it comes to compounding.

It is possible that compounding will play a significant role in the future of healthcare, particularly in the areas of precision medicine and the development of personalized medications for specific individuals. Among these are pharmaceuticals that can be manufactured using a 3D printer for accurate dose and therapeutic formulation. Nanotechnology for better medication delivery systems: Artificial intelligence in the process of pharmaceutical compounding enhances both uniformity and safety. Enhancing the coordination between regulatory agencies is necessary to strike a balance between the protection of patients and the availability of tailored drugs.

Compounding must be integrated into contemporary healthcare while resolving patient safety concerns in order to have a future. If properly handled and used, maintaining the accessibility and safety of patient-specific therapeutic alternatives can connect conventional pharmacy practices with innovative medical breakthroughs. This is under the condition that it is utilized and controlled appropriately. The process of compounding pharmaceuticals has evolved from a need in the past into a specialized operation in contemporary medicine. The practice of compounding is experiencing a return as an essential component of individualized care and specific pharmaceutical requirements. This comes after compounding had a drop in popularity as a result of the advent of bulk drug manufacture. However, compounding has promise in customized therapy, pharmaceutical accessibility, and new prescription compositions. Compounding still has a long way to go before fully realizing its regulatory potential.

ADVANTAGES OF COMPOUNDING MEDICATIONS OVER CONVENTIONAL MEDICINE

Compounding drugs, as opposed to regular pharmaceuticals manufactured in large quantities, have several advantages. Compounding drugs provide patients with individualized treatment alternatives that are individually created to meet their unique requirements, unlike mass-produced pharmaceuticals developed for large populations. This section analyzes the primary advantages of compounded medications, underscoring their relevance in modern healthcare.

Table: A table summarizing the medicines that have been moved and what they now do

Drug	Original Medication	Repositioned Medication
Auranofin	Rheumatoid arthritis	Metronidazole resistant Giardiasis
Crizotinib	Anaplastic large-cell lymphoma	Non-small-cell lung cancer (NSCLC)
Duloxetine	Major depressive disorder	Stress Urinary Incontinence (SUI)
Everolimus	Prevent solid organ transplant rejection, Augment anticancer treatment regimens, Prevent neovascularisation of artificial cardiac stents	Tuberous sclerosis complex
Everolimus	Prevent solid organ transplant rejection, Augment anticancer treatment regimens, Prevent neovascularisation of artificial cardiac stents	Tuberous sclerosis complex
Minoxidil	Hypertension	Androgenic alopecia (Hair loss)
Sildenafil	Angina, chest pain/discomfort	Erectile Dysfunction
Thalidomide	Morning sickness pregnant women	Multiple myelomas
Zidovudine	Anticancer agent	Antiretroviral agent-HIV

1. Care Tailored to Requirements of Individuals: Compounded medicine offers a number of benefits, one of which is the capacity to tailor medicinal formulations to the specific needs of particular patients. Compared to mass-produced pharmaceuticals, which are available in predetermined forms and amounts, compounding offers a greater degree of freedom regarding the dosing form, the composition of the ingredients, and the strength of the drug. It is beneficial for the following:

- Those with incomplete adult prescriptions may discover that sweetened beverages or reduced doses are beneficial.
- Considering how simple it is to consume transdermal gels or liquid formulations, people who are 65 years old or older may find these formulations useful.
- Those individuals who suffer from uncommon medical issues need an unusual concentration of medication.

Modalities of administration are diverse to improve compliance levels. It is difficult for individuals to administer the commercially accessible version of several medications alone. The process of compounding allows pharmacists to alter the route of administration of pharmaceuticals, which improves the meds' palatability and the efficiency with which they are absorbed. You will find a few instances shown below:

- Liquid formulations are made available to those persons who have difficulties swallowing tablets.
- Products such as topical gels and creams for treating localized pain or using anabolic steroids.
- For more rapid absorption, consider using troche or sublingual formulations, which dissolve simply under the tongue.
- Chewable or flavoring pharmaceuticals for dogs and children will be administered to them.
- When it comes to improving drug compliance, those who are experiencing dysphasia, sickness, or gastrointestinal difficulties may find this flexibility to be particularly advantageous.
- The availability of pharmaceuticals that are risk-free for people who suffer from allergies and sensitivities: Some people are allergic to or sensitive to gluten, fillers, colorants, preservatives, and other components in a wide variety of over-the-counter drugs.

The following are examples of formulations that can be created by pharmacists through the process of compounding:

The absence of gluten makes it suitable for individuals who have celiac disease.

It does not contain lactose, which means it is acceptable for individuals who are lactose intolerant.

This product is suitable for individuals with sensitivities or allergies because it does not contain preservatives or dyes.

This guarantees that patients will only receive the required active components, free of any harmful or undesirable excipients.

Medication that has been taken off the market or only available in limited quantities: Individuals dependent on specific prescriptions may have difficulty discovering alternatives if pharmaceutical companies halt manufacturing owing to insufficient sales or problems with the supply chain. It is possible for those who require stopped medications to have them reconstituted at compounding pharmacies using pharmaceutical components. Additionally, compounding helps to alleviate drug shortages by generating alternate prescription formulations that regular pharmacies might not have. This is accomplished through the production of compounded medications.

Combinations of pharmaceutical formulas that are both convenient and effective: Individuals who require many drugs for the same ailment may experience complicated dose regimens and insufficient adherence to their prescribed prescriptions. Compounding is advantageous since it reduces the amount of pills that need to be taken and increases the convenience of the process. This is accomplished by combining a number of different active components into a single dose form.

This is of tremendous benefit in the following way: Because of its versatility, a single formulation may contain several different analgesics in the field of pain treatment.

Hormone replacement treatment, or HRT, involves giving each individual patient a personalized blend of bioidentical hormones. Veterinary medicine allows for the combination of several medications to add

convenience to the administration process. By simplifying drug regimens, compounding improves both adherence and the effectiveness of therapeutic interventions.

The applications of this technology in pediatrics and veterinary medicine: In several circumstances, children and animals require specific treatments inaccessible in conventional commercial forms. These medications are not available in the market.

Among the treatments that can be obtained by compounding are flavored solutions and chewable pills explicitly designed for youngsters. These are pharmaceuticals for animals with a flavor appealing to the human palate, such as chicken, fish, or cattle. Through the modification of doses to accommodate lower body sizes, the therapy was made more secure and prosperous. As a consequence of this, patients in both pediatric and veterinary medicine can access their treatment regimens more successfully and adhere to treatment protocols.

Innovative and Up-to-date Therapeutic Methods and Procedures: Personalized medicine, regenerative medicine, and enhanced drug delivery systems are just some examples of healthcare advances that are rapidly becoming more advanced, and compounding is quickly becoming a key resource for their development.

Many developments are detailed below: An accurate dose may be achieved using 3D-printed medicine. Nanoparticles are used in the development of customized medicinal formulations to improve bioavailability. The efficacy of therapy was improved by implementing more targeted pharmacological delivery techniques. It is anticipated that compounding will play a significant role in the future of precision healthcare, which aims to personalize treatments in accordance with people's genetic and metabolic profiles. The use of compounding, which offers more secure options for the management of pain, can help reduce the negative consequences of opioid addiction and its associated side effects. Patients who are experiencing chronic pain have the option of using customized topical pain creams that contain nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and anesthetics. These creams are far safer than other treatment options. In addition to providing targeted analgesia, these lotions do not absorb into the body's system.

Adherence to dietary restrictions specific to religious and nutritional practices: Certain individuals are prohibited from consuming particular pharmacological components due to the limitations imposed by their religious or nutritional commitments.

The manufacture of compounded drugs can fulfill a wide variety of criteria, including religious compliance. Pharmaceuticals that are declared Halal or Kosher can be manufactured. For the purposes of alternative medicine, products that do not include any components produced from animals are referred to as vegan or vegetarian.

Taking this approach guarantees that everyone will receive the essential treatment while respecting their beliefs and the restrictions they have placed on their diet. Compared to traditional, mass-produced medicines, compounded drugs provide a number of benefits, including the ability to personalize the prescription, formulations free of allergens, and a variety of dose forms that may be adapted to meet the specific needs of each patient. Additionally, compounding makes it easier to manage prescription shortages, discontinued drugs, and specialty treatments for children, pets, and other individuals with specific medical requirements through customized medications.

Compounding has the potential to establish a connection between standardized medication manufacturing and tailored patient care, which is very important in this day and age of customizable therapy and precision medicine. The continued usefulness of compounding as a key component of contemporary healthcare is contingent upon successfully overcoming regulatory constraints, which may be accomplished through the development of pharmaceutical technology and the implementation of stringent safety standards.

REGULATORY APPROACHES FOR ACCESSIBLE COMPOUNDING MEDICATIONS

Regulatory oversight of compounded medications is crucial to maintain quality standards, protect patient safety, and verify the efficacy of pharmaceuticals. Governments and health agencies have addressed the availability of compounded drugs and the necessity for stringent quality control through established recommendations. This section addresses the primary regulatory measures governing compounding pharmacy practices, emphasizing compliance, safety standards, and prospective improvements for accessibility.

Compounding and the Role of Regulatory Authorities: To ensure patient safety and accessibility, compounding techniques are governed by several regulatory authorities. Several instances include:

The FDA formulates and enforces standards for outsourcing facilities as specified in the Drug Quality and Security Act (DQSA) of 2013 and oversees large-scale compounding facilities.

The USP delineates standards for compounding regarding quality and safety in chapters such as USP <795>. USP <797>Non-sterile compounding Sterile compounding is designated USP <800>.

Addressing detrimental pharmaceuticals: Traditional compounding pharmacies are governed by state boards of pharmacy, which oversee adherence to state-specific regulations. Pharmacies meeting high-quality standards may voluntarily seek accreditation from the Pharmacy Compounding Accreditation Board (PCAB). To maintain uniform and safe compounding standards, analogous foreign authorities, like Health Canada, the Therapeutic Goods Administration (TGA) in Australia, and the European Medicines Agency (EMA), enforce these regulations.

Essential Quality and Safety Regulatory Policies: Many regulations have been established to balance accessibility and safety in compounding pharmacy operations. The meningitis outbreak at the New England Compounding Center (NECC) exposed significant issues with unregulated compounding, resulting in the enactment of the Drug Quality and Security Act (DQSA) in the United States in 2013. Classify compounders into two categories: State boards regulate conventional, patient-specific compounding pharmacies classified as 503A pharmacies. Entities classified under the 503B category produce substances in large quantities, are subject to FDA regulation, and must comply with current Good Manufacturing Practices (cGMPs). Before distribution, verify that compounded drugs with a significant risk of adverse effects adhere to rigorous safety protocols.

Criteria Established by the United States Pharmacopeia (USP): Both sterile and non-sterile compounding are regulated by the USP, which encompasses United States Patent No. 795 - Discusses the appropriate selection and storage of ingredients for non-sterile compounding, encompassing creams, capsules, and suspensions. Patent 797 regulates the manufacture of sterile formulations, encompassing injectable and intravenous (IV) medications, which need cleanroom environments and microbiological assessment.

Patent number eight hundred addresses the secure management of potentially hazardous pharmaceuticals, including chemotherapeutic agents, to protect healthcare professionals and patients. Medications are sure to be superior quality, devoid of impurities, and efficacious when adhering to USP standards.

503B outsourcing facilities manufacturing bulk compounded medications must adhere to Good Manufacturing Practices (GMP). Ensures that pharmaceuticals are produced in a sterile environment, assessed for stability, and possess the appropriate potency level.

Guarantees that drug compositions are devoid of contamination risks and discrepancies.

Numerous barriers hinder patients' access to compounded medications despite the existence of rigorous regulations to guarantee their availability: Extensive Prohibitions on Pharmaceutical Compounds: The 503A Bulk Drug List enumerates all compounds that 503A compounding pharmacies are authorized to utilize, as sanctioned by the FDA. Patients may lack access to tailored therapies if particular active pharmaceutical ingredients (APIs) are not readily accessible.

Financial Implications and Compliance Obligations: Small compounding pharmacies face accessibility challenges due to substantial compliance costs. Offering economically priced compounded medications may be challenging due to the

significant sterility and potency testing expenses. Regrettably, several compounded medications lack insurance coverage, rendering them less accessible to those in genuine need. Regulatory initiatives that enhance insurance coverage for essential compounded pharmaceuticals might yield a more cost-effective solution.

Strategies for Improving Future Accessibility While Maintaining Safety: Various strategies can be implemented to achieve a balance between patient accessibility and regulatory compliance. The FDA should prioritize reviewing and expanding the list of authorized bulk medicinal substances for compounding concerning the 503A Bulk Medicine List. In instances where over-the-counter medication is unavailable, pharmacists can formulate their therapy.

The FDA may implement a "priority review" process for essential compounded pharmaceuticals targeting rare diseases, pediatric issues, or chronic conditions, facilitating regulatory paths for these drugs. Decreased regulation of non-sterile, low-risk drugs may enhance availability without jeopardizing patient safety.

Enhancing the Training and Accreditation of Pharmacies: An increasing number of exemplary compounding pharmacies are obtaining PCAB accreditation. This has enhanced Pharmacist education about appropriately managing sterile and non-sterile chemicals. Policymakers and insurance companies should consider funding essential compounded pharmaceuticals if deemed medically necessary. Implementing transparent pricing structures can enhance the affordability of compounded medications for patients.

Enhancing Compounding Safety through Technological Integration: Automated compounding techniques and AI-driven formulation verifications are available to improve precision and reduce human error. Blockchain technology can facilitate establishing a reliable and transparent system for tracking compounded drugs. A balance must be maintained between patient accessibility and stringent safety

protocols in regulatory frameworks for compounding medications. Cost, limitations on bulk ingredients, and insurance restrictions persistently obstruct accessibility despite the oversight of the purity and efficacy of compounded medications by entities such as the FDA, USP, and state pharmacy boards. The enhancement of permitted pharmaceutical lists, the reduction of compliance criteria, the employment of technology, and the promotion of insurance coverage can create a more reliable and accessible compounding option for patients needing personalized therapy. Consequently, adaptable regulatory frameworks that emphasize patient safety while maintaining innovation and accessibility are essential for the sustained success of compounded medicine.

CONCLUSION

The practice of compounding medications has developed from an old method into a modern option for individualized treatment, significantly contributing to the development of medicine. The demand for customized medications has continued to increase despite the total replacement of conventional compounding. This is owing to the fact that patient's particular medical needs, allergies, pediatric and geriatric care, veterinary applications, and bulk drug manufacturing have all contributed to the demand for customized medicines. While compounding can have certain benefits, it also has some drawbacks that should be considered. Accessibility, quality control, and regulatory monitoring are all challenges people face. Compounding is expected to have a bright future as a result of developments in pharmaceutical technology, tight safety standards, and automated compounding machines. Lawmakers, healthcare providers, and regulatory organizations must work together to balance accessibility and safety to guarantee that compounded medications will continue to be accessible to individuals who require them. The practice of compounding will be of critical importance in the future of healthcare, particularly in precision medicine, new pharmaceutical delivery methods, and other improvements. Patients can receive assistance from compounding pharmacies in attaining an appropriate equilibrium between mass manufacturing and tailored therapy by formulating individualized medications and alternate dosage forms to meet their needs. Consequently, compounding pharmaceuticals has a promising future in contemporary medicine despite appearing to be an outdated practice. This is due to the fact that it is both diverse and continues to be of significant importance. In patient-centered healthcare, compounding will continue to be a key component, provided that there are continual innovations and support from regulatory authorities.

REFERENCES

1. Sherr Z, Karara AH. Evaluation of the most frequently prescribed extemporaneously compounded medications in a rural setting: a case study from the Delmarva Peninsula. Int J Pharm Compd. 2014;18:462–468.
2. Cook GK, Ling JWH, Lee R. Extemporaneous compounding in Queensland hospitals. J Pharm Pract Res. 2007;37:204–207.
3. Falconer JR, Steadman KJ. Extemporaneously compounded medicines. Aust Prescr. 2017;40:5–8. doi: 10.18773/austprescr.2017.001.
4. Lyon J. Drug shortage compounding: the only safe medication in a time of crisis. Int J Pharm Compd. 2012;16:456–460.

5. Simoens S, Cassiman D, Picavet E, Dooms M. Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs. Drugs Ther Perspect. 2011;27:24–26.
6. Dooms M, Carvalho M. Compounded medications for patients with rare diseases. Orphanet J Rare Dis. 2018;13:1. doi: 10.1186/s13023-017-0741-y.
7. Gargiulo D, Chemal C, Joda L, et al. Extemporaneous compounding in veterinary practice: a New Zealand perspective. N Z Vet J. 2013;61:311–315. doi: 10.1080/00480169.2013.773853.
8. Kairuz TE, Laksmana I, Steadman KJ. History of extemporaneous compounding in Australia: changes and developments in the Australian Pharmaceutical Formulary. J Pharm Pract Res. 2013;43(2):117–121.
9. Sellers S, Utian WH. Pharmacy compounding primer for physicians: prescriber beware. Drugs. 2012;72:2043–2050. doi: 10.2165/11640850-000000000-00000.
10. Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D. 2013;13:1–8. doi: 10.1007/s40268-013-0005-9.
11. Giam JA, McLachlan AJ, Krass I. Characterizing specialized compounding in community pharmacies. Res Social Adm Pharm. 2012;8:240–252. doi: 10.1016/j.sapharm.2011.05.003.
12. Sellers S, Utian WH. Pharmacy compounding primer for physicians. Drugs. 2012;72:2043–2050. doi: 10.2165/11640850-000000000-00000.
13. Law AV, Gupta EK, Hata M, et al. Collaborative pharmacy practice: an update. Integr Pharm Res Pract. 2013;2:1–16.
14. Nisbet G, Hendry GD, Rolls G, Field MJ. Inter-professional learning for pre-qualification health care students: an outcomes-based evaluation. J Interprof Care. 2008;22:57–68. doi: 10.1080/13561820701722386.
15. Mellor R, Cottrell N, Moran M. “Just working in a team was a great experience.” Student perspectives on the learning experiences of an interprofessional education program. J Interprof Care. 2013;27:292–297. doi: 10.3109/13561820.2013.769093.
16. Taylor S, Fatima Y, Lakshman N, Roberts H. Simulated interprofessional learning activities for rural health care services: perceptions of health care students. J MultidiscipHealthc. 2017:235–241. doi: 10.2147/JMDH.S140989.
17. Hays RB. Interprofessional education in rural practice: how, when and where? Rural Remote Health. 2008;8:939.
18. Mulholland P, Barnett T, Spencer J. Interprofessional learning and rural paramedic care. Rural Remote Health. 2014;14:2821.
19. Mpofu R, Daniels PS, Adonis T-A, Karaguti WM. Impact of an interprofessional education program on developing skilled graduates well-equipped to practice in rural and underserved areas. Rural Remote Health. 2014;14:2671.
20. Schiele JT, Quinzler R, Klimm H-D, Pruszyldo MG, Haefeli WE. Difficulties swallowing solid oral dosage forms in general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol. 2013;69:937–948. doi: 10.1007/s00228-012-1417-0.
21. Chichero JAY. Thickening agents used for dysphagia management: effect on bioavailability of water, medication and feelings of satiety. Nutr J. 2013;12:54. doi: 10.1186/1475-2891-12-54.
22. Rivera JO. Pharmacological management of traumatic brain injury and implications for speech language pathology. Semin Speech Lang. 2014;35:196–203. doi: 10.1055/s-0034-1384681.

23. Krishna Reddy Y, Maheswara Reddy D, Saroja V, Maimoon SK. Transdermal drug delivery system: a review. Res J Pharma Dosage Forns Tech. 2013;5:202–212.
24. Zhao YZ, Du LN, Lu CT, Jin YG, Ge SP. Potential and problems in ultrasound-responsive drug delivery systems. Int J Nanomedicine. 2013;8:1621–1633. doi: 10.2147/IJN.S43589.
25. Schwartz JK, Smith RO. Integration of medication management into occupational therapy practice. Am J Occup Ther. 2017;71:1. doi: 10.5014/ajot.2017.015032.
26. Bakker P, Woerdenbag H, Gooskens, Naafs B, van der Kaiij R, Wieringa N. Dermatological Preparations for the Tropics: A Formulary of Dermatological Preparations and Background Information on Therapeutic Choices, Production and Dispensing. The Netherlands: University of Groningen; 2012. 2nd revised ed.
27. Hawkes G, Nunney I, Lindqvist S. Caring for attitudes as a means of caring for patients – improving medical, pharmacy, and nursing students' attitudes to each other's professions by engaging them in inter-professional learning. Med Teach. 2013;35:1302–1308. doi: 10.3109/0142159X.2013.770129.
28. Hattingh HL, McGuire T, Rogers GD. Inter-professional learning sessions: assessing the impact on medical and pharmacy students. Focus on Health Professional Education: A Multidisciplinary Journal. 2010;12:48–61.
29. Pullon S, Wilson C, Gallagher P, et al. Transition to practice: can rural interprofessional education make a difference? A cohort study. BMC Med Educ. 2016;16:154. doi: 10.1186/s12909-016-0674-5.
30. Anderson E, Lakhani N. Interprofessional learning on polypharmacy. Clin Teach. 2016;13:291–297. doi: 10.1111/tct.12485.
31. Tan ACW, Emmerton LN, Hattingh HL. Issues with medication supply and management in a rural community in Queensland. Aust J Rural Health. 2012;20:138–143. doi: 10.1111/j.1440-1584.2012.01269.x.
32. Tan ACW, Emmerton LN, Hattingh HL, La Caze A. Exploring example models of cross-sector, sessional employment of pharmacists to improve medication management and pharmacy support in rural hospitals. Rural Remote Health. 2015;15:3441.
33. Emden C, Kowanko I, de Crespigny C, Murray H. Better medication management for Indigenous Australians: findings from the field. Aust J Prim Health. 2005;11:80–90.
34. Lau ETL, Jones AL, Kairuz T, Nissen LM, Steadman KJ. Compounding practices in Queensland: experiences and perceptions of pharmacists and pharmacy students. J Pharm Pract Res. 2013;43:19–24.